Market need Target hospitals and liver/cardio-oncology centers treating fluid overload in patients with liver disease, heart failure, and cancer where alfapump and DSR technologies address a common, costly complication and reduce readmissions.

Strategic financing With substantial funding history and a recent financing round extending cash runway, position sequencing of pilot programs or expansion trials in high-need regions, emphasizing time-to-value and ROI for health systems.

Regulatory/commercial Bankruptcy filing indicates a need to monitor continuity of support and service; develop contingency proposals and scalable service agreements to ensure ongoing device maintenance and support for current users.

Clinical adoption Leverage past conference engagement and highlighted alfapump deployments to pursue speaking engagements, case studies, and KOL partnerships that accelerate clinician awareness and patient referrals.

Expansion potential Explore adjacent markets and payer channels by showcasing cost savings from fluid overload management to reduce hospitalizations, potentially expanding use beyond liver and heart failure into oncology and multi-mystem fluids management.